1.70 Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program

<< vissza

Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program
Dátum: 2023-02-06 [news.yahoo.com]

A TELJES HÍR ELOLVASÁSA >>
×